AGP Picks
View all

Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on May 18, 2026

Aesthetic Injectables Market Trends, Investment Opportunities & Growth Analysis Through 2033 Featuring AbbVie, Galderma
Car T Cell Therapy Market Projections 2026-2033: Key Trends, Opportunities, and Growth Factors in New Report|Novartis AG
UbiVac Appoints Walter J. Urba, M.D., Ph.D., to Scientific Advisory Board
Epigenetics Market Demand Rising Rapidly with 15.0% CAGR Through 2033 | Coherent Market Insights
Tooth-Supporting Tissue Breakdown Linked to Key Receptor Loss in Mice
Star Room at Vista del Monte honored for Best Practice/Innovation of the Year
Pennant Group to Participate in the 2026 RBC Global Healthcare Conference
New Lusardi Tower Opens to Patients This Week  At Scripps Memorial Hospital Encinitas
Pennant Announces an Acquisition of Senior Living Community in Arizona
ATI Advisory Launches Public Dashboard on C-SNPs and Eligible Populations
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
 Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
PsyMetrics Releases Healthcare Workforce Benchmark Showing Up to 67% Reduction in Hospital Staff Turnover
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Certara to Participate in Upcoming Investor Conferences
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Share this page:

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.